These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27702709)

  • 1. Lafora disease.
    Turnbull J; Tiberia E; Striano P; Genton P; Carpenter S; Ackerley CA; Minassian BA
    Epileptic Disord; 2016 Sep; 18(S2):38-62. PubMed ID: 27702709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired malin expression and interaction with partner proteins in Lafora disease.
    Skurat AV; Segvich DM; Contreras CJ; Hu YC; Hurley TD; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2024 May; 300(5):107271. PubMed ID: 38588813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatase activity of laforin is dispensable to rescue Epm2a-/- mice from Lafora disease.
    Gayarre J; Duran-Trío L; Criado Garcia O; Aguado C; Juana-López L; Crespo I; Knecht E; Bovolenta P; Rodríguez de Córdoba S
    Brain; 2014 Mar; 137(Pt 3):806-18. PubMed ID: 24430976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
    Mitra S; Chen B; Wang P; Chown EE; Dear M; Guisso DR; Mariam U; Wu J; Gumusgoz E; Minassian BA
    Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36511140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for Lafora disease in the Epm2a
    Zafra-Puerta L; Iglesias-Cabeza N; Burgos DF; Sciaccaluga M; González-Fernández J; Bellingacci L; Canonichesi J; Sánchez-Martín G; Costa C; Sánchez MP; Serratosa JM
    Mol Ther; 2024 Jul; 32(7):2130-2149. PubMed ID: 38796707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
    Vernia S; Rubio T; Heredia M; Rodríguez de Córdoba S; Sanz P
    PLoS One; 2009 Jun; 4(6):e5907. PubMed ID: 19529779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-onset Lafora body disease.
    Turnbull J; Girard JM; Lohi H; Chan EM; Wang P; Tiberia E; Omer S; Ahmed M; Bennett C; Chakrabarty A; Tyagi A; Liu Y; Pencea N; Zhao X; Scherer SW; Ackerley CA; Minassian BA
    Brain; 2012 Sep; 135(Pt 9):2684-98. PubMed ID: 22961547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.
    Sullivan MA; Nitschke S; Steup M; Minassian BA; Nitschke F
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the role of malin in the lafora progressive myoclonus epilepsy.
    Romá-Mateo C; Sanz P; Gentry MS
    IUBMB Life; 2012 Oct; 64(10):801-8. PubMed ID: 22815132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress, a new hallmark in the pathophysiology of Lafora progressive myoclonus epilepsy.
    Romá-Mateo C; Aguado C; García-Giménez JL; Knecht E; Sanz P; Pallardó FV
    Free Radic Biol Med; 2015 Nov; 88(Pt A):30-41. PubMed ID: 25680286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
    Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
    Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.
    Fernández-Sánchez ME; Criado-García O; Heath KE; García-Fojeda B; Medraño-Fernández I; Gomez-Garre P; Sanz P; Serratosa JM; Rodríguez de Córdoba S
    Hum Mol Genet; 2003 Dec; 12(23):3161-71. PubMed ID: 14532330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of leptin signaling reduces polyglucosan inclusions and seizure susceptibility in a mouse model for Lafora disease.
    Rai A; Mishra R; Ganesh S
    Hum Mol Genet; 2017 Dec; 26(24):4778-4785. PubMed ID: 28973665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.